Abstract
Acrp30 is a circulating protein synthesized in adipose tissue. A single injection in mice of purified recombinant Acrp30 leads to a 2-3-fold elevation in circulating Acrp30 levels, which triggers a transient decrease in basal glucose levels. Similar treatment in ob/ob, NOD (non-obese diabetic) or streptozotocin-treated mice transiently abolishes hyperglycemia. This effect on glucose is not associated with an increase in insulin levels. Moreover, in isolated hepatocytes, Acrp30 increases the ability of sub-physiological levels of insulin to suppress glucose production. We thus propose that Acrp30 is a potent insulin enhancer linking adipose tissue and whole-body glucose metabolism.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adipocytes / metabolism*
-
Adiponectin
-
Animals
-
Blood Proteins / metabolism
-
Blood Proteins / physiology*
-
Cell Line
-
Energy Intake
-
Glucose / biosynthesis
-
Humans
-
Hypoglycemic Agents / pharmacology
-
Insulin / physiology*
-
Intercellular Signaling Peptides and Proteins*
-
Liver / physiology*
-
Mice
-
Mice, Inbred C57BL
-
Proteins*
-
Recombinant Proteins / metabolism
-
Thiazoles / pharmacology
-
Thiazolidinediones*
Substances
-
Adiponectin
-
Blood Proteins
-
Hypoglycemic Agents
-
Insulin
-
Intercellular Signaling Peptides and Proteins
-
Proteins
-
Recombinant Proteins
-
Thiazoles
-
Thiazolidinediones
-
2,4-thiazolidinedione
-
Glucose